Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.

@article{Spinelli2004EnzymeRT,
  title={Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.},
  author={Letizia Spinelli and Antonio Pisani and Massimo Sabbatini and Mario Petretta and Maria Vittoria Andreucci and Deni Aldo Procaccini and N Lo Surdo and Stefano Federico and Bruno Cianciaruso},
  journal={Clinical genetics},
  year={2004},
  volume={66 2},
  pages={158-65}
}
Fabry's disease is an X-linked lysosomal storage disease caused by a deficiency of alpha-galactosidase that results in an accumulation of neutral glycosphingolipids throughout the body, including the cardiovascular system. Fabry cardiomyopathy, characterized by progressive severe concentric left ventricular (LV) hypertrophy, is very frequent and is the most important cause of death in affected patients. Enzyme replacement therapy (ERT) allows a specific treatment for this disease, however… CONTINUE READING
40 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

Similar Papers

Loading similar papers…